A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters

Article activity feed

1. 

   ScreenIT

   Jul 9, 2021

   SciScore for 10.1101/2021.07.06.451301: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IACUC: Animal experiments: All the animal experiments were performed in accordance with protocols approved by the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC).
   Sex as a biological variable	Mouse immunization and challenge studies: Female BALB/c mice were used in all studies.
   Randomization	not detected.
   Blinding	All sections were evaluated by a veterinary pathologist who was blinded to the vaccination groups in the Comparative Pathology Laboratory (CPL) at ISMMS.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   An HRP-conjugated goat anti-mouse IgA secondary antibody (PA1-74397 Invitrogen) was …

   SciScore for 10.1101/2021.07.06.451301: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IACUC: Animal experiments: All the animal experiments were performed in accordance with protocols approved by the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC).
   Sex as a biological variable	Mouse immunization and challenge studies: Female BALB/c mice were used in all studies.
   Randomization	not detected.
   Blinding	All sections were evaluated by a veterinary pathologist who was blinded to the vaccination groups in the Comparative Pathology Laboratory (CPL) at ISMMS.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   An HRP-conjugated goat anti-mouse IgA secondary antibody (PA1-74397 Invitrogen) was used at 1: 2000 dilution.	anti-mouse IgA suggested: (Thermo Fisher Scientific Cat# PA1-74397, RRID:AB_10985723)
   The plaques were immuno-stained with an anti-SARS-CoV-2 NP primary mouse monoclonal antibody 1C7C7 kindly provided by Dr. Thomas Moran at ISMMS.	anti-SARS-CoV-2 NP suggested: None
   An HRP-conjugated goat anti-mouse secondary antibody was used at 1:2000 and the plaques were visualized using TrueBlue™ Peroxidase Substrate (SeraCare Life Sciences Inc.).	anti-mouse suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Viral titers in the lung homogenates were measured by plaque assay on Vero E6 cells.	Vero E6 suggested: RRID:CVCL_XD71)
   Experimental Models: Organisms/Strains
   Sentences	Resources
   Mouse immunization and challenge studies: Female BALB/c mice were used in all studies.	BALB/c suggested: RRID:IMSR_ORNL:BALB/cRl)
   Recombinant DNA
   Sentences	Resources
   The sequence of the HXP-S was inserted into pNDV_LS/L289A rescue plasmid (between P and M genes) by in-Fusion cloning (Clontech).	pNDV_LS/L289A suggested: None
   The recombination product was transformed into MAX Efficiency™ Stbl2™ Competent Cells (Thermo Fisher Scientific) to generate the pNDV-HXP-S rescue plasmid.	pNDV-HXP-S suggested: None
   The next day, cells were transfected with 2 μg of pNDV-HXP-S, 1 μg of pTM1-NP, 0.5 μg of pTM1-P, 0.5 μg of pTM1-L and 1 μg of pCI-T7opt were re-suspended in 250 μL of Opti-MEM (Gibco).	pTM1-NP suggested: None pTM1-P suggested: None pTM1-L suggested: None pCI-T7opt suggested: None
   Software and Algorithms
   Sentences	Resources
   Statistical analysis: The statistical analysis was performed using GraphPad Prism 7.0.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
   

   Identifier	Status	Title
   NCT04764422	Recruiting	Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in…
   NCT04830800	Recruiting	A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vacc…
   NCT04871737	Recruiting	Study of a Live rNDV Based Vaccine Against COVID-19

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
2. 

   Version published to 10.1101/2021.07.06.451301v1 on bioRxiv

   Jul 7, 2021